Good morning, welcome to PMV Pharmaceuticals Incorporated 2026 Annual Meeting of Stockholders. I would like to introduce David Mack, the company's President, Chief Executive Officer, and member of the board of directors. Dr. Mack, please go ahead. Thank you. Good morning, ladies and gentlemen. It is a pleasure to welcome you to the 2026 Annual Meeting of Stockholders. We'll begin today with the formal business of the meeting and will provide time for questions after the formal business of this meeting is adjourned. The agenda for the meeting should be displayed on your screen during the webcast. We are holding a virtual annual meeting of stockholders, which means the annual meeting takes place exclusively via internet webcast. Stockholders attending the virtual meeting via internet webcast may vote their shares online in real time until the polls are closed at the conclusion of the formal portion of business at this meeting. The polls to vote online are currently open. If you already submitted a proxy to vote your shares, you do not need to submit an online ballot unless you want to change your vote. Before proceeding further, I'd like to note that Robert Ticktin, our General Counsel, Chief Operating Officer, and Corporate Secretary, is virtually present at this meeting. Finally, I'd like to note that representatives from our independent registered public accounting firm, Ernst & Young, LLP, and from Wilson Sonsini Goodrich & Rosati, our legal counsel, are present at this meeting. We have asked Robert Ticktin to record the minutes of this meeting, and Lou Larson of Broadridge Financial Solutions, Inc. to serve as Inspector of Election. This annual meeting is being held in accordance with the company's bylaws and Delaware law. During the formal meeting, we will address the matters described in the company's proxy statement dated April 22nd, 2026. This meeting will be conducted in accordance with the rules of conduct, which are available to each of you on the webcast portal. The rules of conduct have been established to provide for an orderly and informative meeting, and we thank you for your cooperation in following them. As we complete the formal meeting, we will have a Q&A session and provide responses to any appropriate questions. Only registered stockholders may ask questions in the designated field on the web portal. To ask a question on the web portal, click on the Q&A button to open the panel, enter your question in the field labeled Ask a Question, and click Submit. I'll now turn it over to our General Counsel and Chief Operating Officer, Robert Ticktin. Thanks, David. We will now proceed with the formal portion of this meeting. I have proof by affidavit that notice of this meeting has been duly given and that the notice, proxy statement, and proxy were mailed on or about April 22nd, 2026 to all stockholders of record on April 7th, 2026, the record date for this annual meeting. We have made available online during this meeting a list of the registered stockholders as of that date. The affidavit of mailing, together with copies of the notice, proxy statement, and proxy, will be filed with the minutes of this meeting. The Inspector of Election has signed the oath of the Inspector of Election, which will also be filed with the minutes of this meeting. The Inspector of Election has advised me that we have present in person and by proxy a sufficient number of shares to constitute a quorum, so the meeting is duly constituted. For the purposes of this annual meeting, we will vote by proxy and by our online voting polls. If you are attending this meeting using your 16-digit control number, you can vote your shares by clicking the Vote Here button and following the instructions. Each holder of common stock is entitled to one vote for each share of common stock held of record at the close of business on the record date. If you have turned in a proxy and do not intend to change your vote, then it is not necessary that you vote because we will count your proxy. Those of you who did not turn in a proxy or who wish to change your vote may vote virtually on the website used to access this meeting and following the instructions. We will provide preliminary voting results at the end of the meeting. It is now 10:04 A.M. Eastern Time on June 4th, 2026. The polls are now open to vote on the following matters. If you've already sent in a proxy or voted via the telephone or internet and do not wish to change your vote, no further action is needed. There are three proposals to be considered and voted upon by our stockholders today. The first proposal is the election of two Class III directors. This item is discussed more fully on page 35 of the proxy statement. The company's board of directors presently has seven members and is divided into three classes with staggered three-year terms. Dr. Heyman's term of office as a Class III director and service as the chairperson of our board of directors expires at this meeting. Dr. Heyman will not stand for re-election. Effective as of this meeting, the number of directors of the company's board of directors will be reduced from seven to six, consisting of two Class I directors, two Class II directors, and two Class III directors. Accordingly, today, we are electing two Class III directors. The directors that the stockholders elect at today's meeting will hold office until the 2029 annual meeting of stockholders or until their respective successors are duly elected and qualified. As indicated in the company's proxy statement, the board of directors nominated David Mack and Laurie Stelzer to serve as our Class III directors until our 2029 annual meeting of stockholders or until their respective successors are elected and qualified. Pursuant to the notice of this annual meeting and the proxy statement, the proxies solicited by the board of directors will be voted in favor of the nominees. Our board of directors recommends a vote for the election of each of Dr. Mack and Ms. Stelzer to act as Class III directors for a three-year term, or until their respective successors are elected and qualified. The second proposal is the approval on a non-binding advisory basis of the compensation of our named executive officers. This item is discussed more fully on page 36 of the proxy statement. You are encouraged to review the section titled "Executive Compensation" in the proxy statement, which provides additional information regarding our executive compensation program. Although the vote is non-binding, our board of directors and our compensation committee value the opinions of our stockholders and will consider the outcome of the vote when making future compensation decisions for our named executive officers. Our board of directors recommends a vote for the approval on a non-binding advisory basis of the compensation of our named executive officers. The third proposal is the ratification of the appointment of the firm Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year, which will end on December 31, 2026. This item is discussed more fully on page 37 of the proxy statement. The audit committee of our board of directors selects the company's independent registered public accounting firm annually. The audit committee has appointed Ernst & Young as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The audit committee is asking the stockholders for ratification of their appointment. Stockholder ratification is not required by the company's bylaws or other applicable legal requirements. However, the audit committee is submitting the appointment to the stockholders for ratification as a matter of good corporate governance and because we value our stockholders' views on the company's independent registered public accounting firm. Our board of directors recommends a vote for the ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the next fiscal year. It is now 10:09 A.M. Eastern Time on June 4th, 2026, and the polls for proposals one, two, and three are now closed. No additional ballots, proxies, or votes and changes or revocations will be accepted. We will now review the preliminary report for the proposals that were voted on at the meeting today. Any votes cast today, including those submitted electronically during the meeting, will be counted in the final voting tally, which will be reported on a Form 8-K that we file with the SEC within four business days of this meeting. The Inspector of Elections has delivered a preliminary report of the voting results, which shows Dr. Mack and Ms. Stelzer have been elected as the Class III directors of PMV Pharmaceuticals. The compensation of our named executive officers on a non-binding advisory basis was approved, and the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, has been ratified. There being no further business to come before this meeting, this annual meeting of stockholders is now adjourned. Thank you for your attendance at the formal portion of the meeting. We will now respond to questions that are germane to the meeting as time allows. Before we begin, I would like to note that our responses to your questions today may include forward-looking statements. Actual results could differ materially from those contemplated by our forward-looking statements. Reported results should not be considered as an indication of future performance. Please take a look at our filings with the SEC for a discussion of the factors that could cause our results to differ. Also note that any forward-looking statements are based on information available to us as of today's date, and we disclaim any obligation to update any forward-looking statements except as required by law. There are no questions to address. As a result, I will now hand it back over to you, Dr. Mack. Well, on Dr. Mack's behalf, I want to thank everyone. Oh, I am sorry. I apologize. I was on mute. No worries. Okay. Thank you, Robert. I want to thank all of you for attending today's meeting and for your interest you have shown in the affairs of our company. We very much appreciate your attendance, and as always, thank you for your support. This concludes our meeting. You may now disconnect.